On Jun. 16, 2021, CureVac announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (HERALD study) of CureVacﾒs first-generation COVID-19 vaccine candidate, CVnCoV.

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. Initial analyses suggest age and strain dependent efficacy. Available data were communicated with the European Medicines Agency (EMA). The Data Safety Monitoring Board (DSMB) confirmed a favorable safety profile for CVnCoV.